An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
This trial found that an intradialytic cycling programme did not improve health-related quality of life compared with usual care.
1 King’s College Hospital NHS Foundation Trust, London, UK
2 School of Renal Medicine, King’s College London, London, UK
3 School of Health Sciences, Queen Margaret University, Edinburgh, UK
4 School of Sport, Health and Exercise Sciences, Bangor University, Bangor, UK
5 Hull University Teaching Hospitals NHS Trust, Hull, UK
6 Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
7 University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
8 Lister Hospital, Stevenage, UK
9 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
10 Salford Royal Hospital, Salford, UK
11 Glan Clwyd Hospital, Bodelwyddan, UK
12 Manchester University Hospitals, Manchester, UK
13 Department of Health Sciences, University of Leicester, Leicester, UK
14 School of Medicine, University of Nottingham, Nottingham, UK
15 Queen Elizabeth University Hospital, Glasgow, UK
16 School of Medicine, University College London, London, UK
17 George Institute for Global Health, Sydney, NSW, Australia
18 Royal London Hospital, London, UK
* Corresponding author Email: sharlene.greenwood@nhs.net
Declared competing interests of authors: David C Wheeler reports personal fees from Amgen Inc. (Thousand Oaks, CA, USA), AstraZeneca plc (Cambridge, UK), Bayer AG (Leverkusen, Germany), C.H. Boehringer Sohn AG & Co. KG (Ingelheim am Rhein, Germany), GlaxoSmithKline plc (Brentford, UK), Janssen Pharmaceuticals (Beerse, Belgium), Mundipharma International Ltd (Cambridge, UK), Napp Pharmaceutical Group Ltd (Cambridge, UK), Merck Sharp & Dohme Corp. (Kenilworth, NJ, USA), Astellas Pharma Inc. (Tokyo, Japan), Tricida (South San Francisco, CA, USA) and Vifor Fresenius Medical Care Renal Pharma Ltd (Glattbrugg, Switzerland). Sandip Mitra’s research is supported by National Institute for Health Research Infrastructure in Manchester and D4D MIC (Devices for dignity national MedTech and In vitro diagnostic Co-operatives) Sheffield.
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document